1.中国防痨协会结核病监测专业分会委员
2.上海市微生物协会会员
1.Member of the Tuberculosis Surveillance Committee of the Chinese Anti-Tuberculosis Association
2.Member of Shanghai Microbiology Association
周迎2022年获得国家自然科学基金青年科学基金项目资助，并同年入选上海市科委启明星计划（扬帆专项）。以第一及通讯作者（包括共同）在Drug Resistance Updates，eBiomedicine，Emerging Infectious Disease等微生物感染领域权威期刊发表SCI 18篇，累计影响因子接近100，其中包括5篇中科院1区期刊。
主要学术成果包括：（1）在耐药细菌传播机制方面：2022年在中国大陆首次报道了IncX8质粒介导的产KPC-3碳青霉烯耐药肠杆菌科细菌的爆发，并系统阐释该质粒结构特点（Emerging Infectious Disease，2022）；从宿主菌免疫系统角度阐释了细菌携带的CRISPR-Cas等免疫系统在影响耐药质粒传播过程中所发挥的作用（Emerging Microbes & Infections，International Journal of Antimicrobial Agents，Journal of Antimicrobial Chemotherapy）。（2）在防控耐药菌传播新型策略探究方面：创新性地探究肺炎克雷伯菌携带的天然CRISPR-Cas3 系统在消除耐药质粒的应用，为耐药菌感染的治疗、防控和去定植提供全新的角度（eBiomedicine，Lancet 子刊，2023）。法国巴斯德研究所Didier Mazel教授在最新发表的综述对该工作进行述评，并阐释该方法的应用前景。（3）探究高毒高耐菌株致病和传播机制：发现ST11-KL64 型CR-hvKP具有耐药谱广和致病性高的特点，并且可有效将毒力质粒诱动传播至更多的CRKP菌株（Drug Resistance Updates，2023）。
In 2022, Dr. Zhou received funding from the National Natural Science Foundation of China Youth Science Fund Project and was selected for the Shanghai Science and Technology Commission Morning Star Program (Yangfan Project) in the same year. She has published 18 SCI articles as the first and corresponding author (including co-author) in authoritative journals in the field of microbial infection, such as Drug Resistance Updates, eBiomedicine, and Emerging Infectious Disease, with a cumulative impact factor of nearly 100, including 5 articles in the first zone journals of the Chinese Academy of Sciences.
The main academic achievements include: (1) In terms of the transmission mechanism of drug-resistant bacteria: In 2022, the outbreak of KPC-3 carbapenem-resistant Enterobacteriaceae mediated by IncX8 plasmid was reported for the first time in mainland China, and the structural characteristics of the plasmid were systematically explained (Emerging Infectious Disease, 2022); from the perspective of the host bacterial immune system, the role of the immune system such as CRISPR-Cas carried by bacteria in affecting the transmission of drug-resistant plasmids was explained (Emerging Microbes & Infections, International Journal of Antimicrobial Agents, Journal of Antimicrobial Chemotherapy). (2) In terms of exploring new strategies for preventing and controlling the spread of drug-resistant bacteria: Innovatively explore the application of the natural CRISPR-Cas3 system carried by Klebsiella pneumoniae in eliminating drug-resistant plasmids, providing a new perspective for the treatment, prevention and control, and decolonization of drug-resistant bacterial infections (eBiomedicine, a Lancet sub-journal, 2023). Professor Didier Mazel of the Pasteur Institute in France commented on this work in his latest review and explained the application prospects of this method. (3) Exploring the pathogenicity and transmission mechanism of highly toxic and highly resistant strains: It was found that the ST11-KL64 type CR-hvKP has the characteristics of a wide spectrum of drug resistance and high pathogenicity and can effectively induce the spread of virulence plasmids to more CRKP strains (Drug Resistance Updates, 2023).
